$10.6 billion acquisition delivers a key return! GlaxoSmithKline plc Sponsored ADR (GSK.US) lung cancer drug Nelkarmi approved for marketing, targeting a multi-billion-dollar market

date
07:23 18/11/2026
avatar
GMT Eight
GlaxoSmithKline's lung cancer drug neladalkib has received marketing approval from the U.S. Food and Drug Administration (FDA), further validating the strategic value of the British pharmaceutical company's earlier acquisition of biotechnology company Nuvalent.
GlaxoSmithKline plc Sponsored ADR's (GSK.US) lung cancer drug neladalkib has received marketing approval from the U.S. Food and Drug Administration (FDA), offering a new treatment option for patients whose disease still progresses after prior ALK-targeted therapy and further validating the strategic value of the British pharmaceutical company's earlier acquisition of biotechnology company Nuvalent. The drug will be marketed under the brand name Nelkarmi and is approved for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) driven by ALK gene mutations. Specifically, the eligible population includes patients who, in the unresectable locally advanced or metastatic setting, have previously received one ALK tyrosine kinase inhibitor (TKI), alectinib, or have previously received two or more ALK TKIs plus platinum-based chemotherapy. ALK gene abnormalities cause abnormal cell growth and are an important pathogenic factor in some non-small cell lung cancers. Nelkarmi's U.S. accelerated approval was based primarily on data from the Phase I/II ALKOVE-1 clinical trial. The trial is a multicenter, open-label study designed to evaluate the efficacy and safety of neladalkib in patients with advanced ALK-positive non-small cell lung cancer who had previously received ALK-targeted therapy. The primary efficacy analysis supporting the FDA approval included a total of 222 patients, of whom 67 had previously received only alectinib and another 155 had previously received two or more ALK TKIs plus platinum-based chemotherapy. Trial results showed that among patients who had previously received only alectinib, Nelkarmi achieved a confirmed objective response rate (ORR) of 49%; among patients who had previously received two or more ALK TKIs and platinum-based chemotherapy, the objective response rate was 32%. In terms of duration of response (DOR), among the former group, 76% of responders had a duration of response of at least 6 months and 52% of at least 12 months; the corresponding proportions in the latter group were 69% and 51%, respectively. More notably, the drug also demonstrated some efficacy in patients with brain metastases. Among patients with measurable central nervous system (CNS) metastatic lesions at baseline, the intracranial objective response rate was 55% in patients who had previously received only alectinib, including a complete response rate of 25%; the intracranial objective response rate was 26% in patients who had previously received two or more ALK TKIs and platinum-based chemotherapy, including a complete response rate of 11%. This means Nelkarmi is expected to provide a new solution for the brain metastases and post-treatment resistance problems commonly seen in ALK-positive lung cancer patients. In terms of safety, the most common adverse reactions include hepatotoxicity, musculoskeletal pain, constipation, dysgeusia, peripheral neuropathy, edema, and fatigue. The proportion of patients who permanently discontinued treatment due to adverse reactions was 5%. Compared with existing ALK-targeted drugs, Nelkarmi adopts a next-generation highly selective ALK inhibitor design aimed at more broadly covering ALK resistance mutations while improving the drug's ability to penetrate the blood-brain barrier to address clinical challenges such as brain lesions and treatment resistance. However, its full efficacy still awaits further verification. GlaxoSmithKline plc Sponsored ADR is conducting a Phase III clinical trial called ALKAZAR to evaluate the drug as first-line treatment for ALK-positive non-small cell lung cancer and compare it with the existing standard therapy alectinib. Investors have high hopes for this drug. Before the drug's approval, Jefferies Financial Group Inc. analyst Michael Leuchten said in a note to clients that Nelkarmi has "considerable upside potential" through 2030 and beyond. Analysts surveyed by media expect the drug's sales to reach about US$1 billion in 2023. The acquisition of Nuvalent is an important part of GlaxoSmithKline plc Sponsored ADR's strategy under new Chief Executive Officer Luke Miels to expand its oncology drug portfolio. Miels is currently under pressure to revitalize the company's research and development pipelinemany investors believe GlaxoSmithKline plc Sponsored ADR's pipeline has failed to keep pace with competitors. Earlier this year, GlaxoSmithKline plc Sponsored ADR acquired Nuvalent for US$10.6 billion and completed the transaction in July this year. This is also the company's largest acquisition to date. From a strategic perspective, the core value of the deal lies in GlaxoSmithKline plc Sponsored ADR gaining at once two late-stage clinical next-generation precision-targeted lung cancer drugs with blockbuster potential, as well as a series of earlier-stage R&D assets. Among them, in addition to neladalkib, the ALK-targeted drug corresponding to Nelkarmi, the other drug zidesamtinib (brand name Jideytro) is a next-generation ROS1 selective inhibitor that received FDA approval in July this year for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer who have previously received a ROS1 kinase inhibitor. This drug is likewise designed to address issues such as resistance mutations, brain metastases, and treatment tolerability faced by existing therapies. In addition, Nuvalent also has a HER2-targeted drug NVL-330 in Phase I clinical trials, as well as multiple preclinical R&D projects. This means that through this acquisition, GlaxoSmithKline plc Sponsored ADR not only obtained two innovative lung cancer drugs that can be commercialized relatively quickly, but also further improved its R&D layout across key oncogenic targets such as ALK, ROS1, and HER2, providing a new platform for future expansion in the lung cancer treatment market. It is worth noting that the deal is also expected to help GlaxoSmithKline plc Sponsored ADR accelerate its return to the oncology drug market. The company had previously spun off its oncology business and has since gradually rebuilt the related portfolio through a series of acquisitions and collaborations. With two Nuvalent drugs successively receiving FDA approval, GlaxoSmithKline plc Sponsored ADR now has new commercial products in the lung cancer field and is expected to leverage growth in the precision-targeted therapy market to increase the share of oncology business in overall revenue. From a commercial outlook perspective, GlaxoSmithKline plc Sponsored ADR previously said that both core Nuvalent drugs have the potential to become multi-blockbusters. Jefferies Financial Group Inc. analysts expect combined peak sales of the two drugs to reach US$5 billion to US$7 billion in the future. If these expectations are realized, the US$10.6 billion acquisition is expected to become an important growth engine for GlaxoSmithKline plc Sponsored ADR over the next several years and help the company cope with patent expiration pressure facing some existing drugs in the future. Hesham Abdullah, GlaxoSmithKline plc Sponsored ADR's head of oncology R&D, said at a briefing: "I think we are making very good progress in the oncology portfolio." He said the company is building a lung cancer drug franchise while other drugs targeting blood cancers and gastrointestinal cancers and other diseases are also in development.